[Federal Register: September 20, 2002 (Volume 67, Number 183)]
[Notices]               
[Page 59271]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr20se02-58]                         

-----------------------------------------------------------------------

DEPARTMENT OF DEFENSE

Department of the Army

 
Availability for Non-Exclusive, Exclusive, or Partially Exclusive 
Licensing of U.S. Patent Application Concerning Compositions for 
Treatment of Hemorrhaging With Activated Factor VIIa in Combination 
With Fibrinogen and Methods of Using Same

AGENCY: Department of the Army, DOD.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: In accordance with 37 CFR 404.6 and 404.7, announcement is 
made of the availability for licensing of U.S. Patent Application No. 
09/756,907 entitled ``Compositions for Treatment of Hemorrhaging with 
Activated Factor VIIa in Combination with Fibrinogen and Methods of 
Using Same,'' filed January 10, 2001. Foreign rights (PCT/US01/00725) 
are also available. The United States Government, as represented by the 
Secretary of the Army has rights in this invention.

ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, 
ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick, 
Frederick, MD 21702-5012.

FOR FURTHER INFORMATION CONTACT: For patent issues, Ms. Elizabeth 
Arwine, Patent Attorney, (301) 619-7808. For licensing issues, Dr. Paul 
Mele, Office of Research & Technology Assessment, (301) 619-6664, both 
at telefax (301) 619-5034.

SUPPLEMENTARY INFORMATION: The combination of recombinant factor VIIa 
and fibrinogen is effective in treatment for bleeding where direct 
pressure, tourniquets, indirect pressure, surgical ligation, bandaging, 
and transfusion of blood or plasma products are typically used. The 
combination of factor VIIa and fibrinogen is administered 
intravenously, either sequentially or simultaneously. The compositions 
may be safely circulated in the blood vessels to sites of injury. This 
is effective for single or multiple external or internal wounds.

Luz D. Ortiz,
Army Federal Liaison Officer.
[FR Doc. 02-23852 Filed 9-19-02; 8:45 am]
BILLING CODE 3710-08-M